Sumitomo Dainippon Pharma Co., Ltd

(PINK:DNPUF)

Latest On Sumitomo Dainippon Pharma Co., Ltd (DNPUF):

Date/Time Type Description Signal Details
2022-10-25 05:51 ESTNewsMyovant Sciences cancels Q2 earnings call in light of Sumitovant acquisitionN/A
2022-10-24 16:06 ESTNewsMyovant stock pops as Sumitovant to acquire remaining stake for $1.7BN/A
2021-07-22 13:45 ESTNewsNabriva antibiotic meets primary endpoint in phase 3 trial; shares soar 40%N/A
2021-03-30 06:09 ESTDividendA dividend of $14 has been announced on May 13, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021.Neutral
2021-01-29 13:23 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 23:08 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 02:10 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 18:31 ESTFinancialsCompany financials have been released.Neutral
2020-11-02 09:52 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 15:23 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 07:33 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 11:26 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 15:01 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 10:47 ESTFinancialsCompany financials have been released.Neutral
2020-08-02 10:22 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 19:12 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 07:10 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 23:23 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 15:02 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 19:49 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 11:14 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 18:56 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 02:44 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 14:50 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 06:57 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 08:31 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 07:34 ESTFinancialsCompany financials have been released.Neutral
2020-05-24 10:19 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 03:15 ESTFinancialsCompany financials have been released.Neutral
2020-05-17 02:10 ESTNewsStocks To Watch: Retail Heavyweights, Nvidia, Bristol-Myers And 5G PlaysN/A
2020-05-06 07:51 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 18:45 ESTFinancialsCompany financials have been released.Neutral
2020-04-20 06:33 ESTFinancialsCompany financials have been released.Neutral
2020-04-09 22:39 ESTFinancialsCompany financials have been released.Neutral
2020-04-09 10:24 ESTFinancialsCompany financials have been released.Neutral
2020-04-03 23:09 ESTFinancialsCompany financials have been released.Neutral
2020-03-30 06:13 ESTDividendA dividend of $14 has been announced on May 10, 2019. It will be paid Jan 1, 1970 with an ex-dividend date of Mar 30, 2020.Neutral
2020-03-25 22:39 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 06:12 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 00:15 ESTFinancialsCompany financials have been released.Neutral
2020-02-22 01:46 ESTFinancialsCompany financials have been released.Neutral
2020-02-21 01:17 ESTFinancialsCompany financials have been released.Neutral
2020-02-18 01:33 ESTFinancialsCompany financials have been released.Neutral
2020-02-13 01:47 ESTFinancialsCompany financials have been released.Neutral

About Sumitomo Dainippon Pharma Co., Ltd (DNPUF):

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

See Advanced Chart

General

  • Name Sumitomo Dainippon Pharma Co., Ltd
  • Symbol DNPUF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 6,457
  • Fiscal Year EndMarch
  • Web URLhttp://www.ds-pharma.com
View More

Valuation

  • Trailing PE 11.5
  • Forward PE 15.2
  • Price/Sales (Trailing 12 Mt.) 1.37
  • Price/Book (Most Recent Quarter) 1.31
  • Enterprise Value Revenue 0.02
  • Enterprise Value EBITDA 0.07
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 13%
  • Return on Assets 5%
  • Return on Equity 9%
  • Revenue Per Share $0
  • Gross Profit 353.06 billion
  • Quarterly Earnings Growth 5.4%
View More

ESG Rating

  • Rating Date 2019-01-01
  • ESG Score 30.4
  • Environment Score 5.62
  • Social Score 18.06
  • Governance Score 15.73
  • Controversy Level 1
View More

Highlights

  • Market Capitalization 7.54 billion
View More

Share Statistics

  • Shares Outstanding 397.3 million
  • Shares Float 173.82 million
  • % Held by Insiders 5925%
  • % Held by Institutions 18.59%
View More

Technicals

  • Beta 0.39
  • 52 Week High $16.5
  • 52 Week Low $12.15
  • 50 Day Moving Average 15.83
  • 200 Day Moving Average 14.07
View More

Dividends

  • Forward Annual Dividend Rate $0.26
  • Forward Annual Dividend Yield 1.58%
  • Payout Ratio 16%
  • Dividend Date N/A
  • ExDividend Date 2021-03-30
  • Dividend Per Share $0.26
  • Dividend Yield 0%
View More

Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Dividend Calendar:

Sumitomo Dainippon Pharma Co., Ltd pays out 16% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A$0.79
2020-09-302020-12-31$N/A$0.80$17.15-95.32%
2020-06-302020-09-30$N/A$0.45$19.66-97.69%
2020-03-312020-06-30$N/A$0.43$31.92-98.67%
2019-12-312020-03-31$126.41 billion-$0.08$20.58-100.37%
2019-09-302019-12-31$113.12 billion$0.32$9.24-96.58%
2019-06-302019-09-30$117.48 billion$0.55$28.20-98.05%
2019-03-312019-06-30$112.4 billion$0.16$23.70-99.34%
2018-12-312019-03-31$120.72 billion$0.20$22.10-99.11%
2018-09-302018-12-31$16.05 billion$0.28$18.80-98.52%
2018-06-302018-09-30$3.79 billion$0.28$28.05-99%
2018-03-312018-06-30$102.72 billion$0.35$21.00-98.35%
2017-12-312018-03-31$1.94 billion$0.07$20.85-99.68%
2017-09-302017-12-31$4.09 billion$0.35
2017-06-302017-09-30$116.3 billion$0.46$22.65-97.98%
2017-03-312017-06-30$106.13 billion$0.32$11.70-97.24%
2016-12-312017-03-31-$0.01$19.40-100.07%
2016-09-302016-12-31$0.40$15.40-97.39%
2016-06-302016-09-30$0.06$13.40-99.53%
2016-03-312016-06-30$0.21$7.70-97.34%
2015-12-312016-03-31$0.03$9.70-99.69%
2015-09-302015-12-31$0.21$10.10-97.9%
2015-06-302015-09-30$0.15
2015-03-312015-06-30$0.12
2014-12-312015-03-31-$0.07$15.10-100.49%
2014-09-302014-12-31$0.15$21.80-99.3%
2014-06-302014-09-30$0.14
2014-03-312014-06-30$0.14
2013-12-312014-03-31$0.02
2013-09-302013-12-31$0.25
2013-06-302013-09-30$0.10
2013-03-312013-06-30$0.12
2012-12-312013-03-31-$0.18
2012-09-302012-12-31$0.17
2012-06-302012-09-30$0.17
2012-03-312012-06-30$0.18
2011-12-312012-03-31-$0.05
2011-09-302011-12-31$0.02
2011-06-302011-09-30$0.05
2011-03-312011-06-30$0.25
2010-12-312011-03-31$0.06
2010-09-302010-12-31$0.19
2010-06-302010-06-30$0.25
2010-03-312010-03-31-$0.01
2009-12-312009-12-31$0.24

Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Chart:

Sumitomo Dainippon Pharma Co., Ltd (DNPUF) News:

Below you will find a list of latest news for Sumitomo Dainippon Pharma Co., Ltd (DNPUF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Sumitomo Dainippon Pharma Co., Ltd (DNPUF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link